Fig. 3From: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registryMeasures of treatment efficacy over time. Rates of Juvenile Disease Activity Score (JADAS)10-minimal disease activity (JADAS10 ≤ 3.8) and JADAS10-remission (JADAS10 ≤ 1) and rates of patients reaching inactive disease according to Wallace et al. [13] upon etanercept treatmentBack to article page